Exelixis Inc. Common Stock (EXEL)

FairStock Score: 80/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a business that earns real cash and does not need much debt. Exelixis fits much of that picture. It sells oncology medicines, chiefly CABOMETYX and COMETRIQ, in the United States. In the quarter ended 2026-07-03, fiscal Q2 2026, revenue was $628.7 million, net income $212.1 million, and diluted EPS $0.82. A year earlier, in the quarter ended 2025-07-04, revenue was $568.3 million, net income $184.8 million, and diluted EPS $0.65. Sales grew about 10.6% and profits grew about 14.8% on those filed figures. For FY2025, the fiscal year ended 2026-01-02, revenue was $2.3 billion, net income $782.6 million, and diluted EPS $2.78, up from FY2024, the fiscal year ended 2025-01-03, when net income was $521.3 million and diluted EPS $1.76. The balance sheet is conservative: FairStock shows D/E of 0.09, Altman Z-Score of 14.46, Piotroski F-Score 7/9, ROE 44.39%, ROCE 23.97%, and trailing free cash flow of $1.2 billion, a 7.9% FCF yield. That is a high-quality financial profile. The moat, however, is narrower than the numbers suggest: the company depends heavily on a few cabozantinib products, and patent and competitive risks matter. At the 2026-10-13 close of $59.51, FairStock calculates P/E 18.71, P/B 8.03, PEG 1.27, EV/EBITDA 14.34, and a Graham Number of $23.03, implying the price is far above asset-based value. FairStock calls it a FAST GROWER, based on five-year profit growth of 47.6% a year and revenue growth of 18.6%. I would call it a good business at a fair-to-full price, not a bargain.

In plain English: Exelixis is a cancer-drug company that sells medicines such as CABOMETYX and COMETRIQ, mostly in the United States. The business looks strong: sales and profits are growing, it is solidly profitable, and it carries little debt. The stock price looks fair to a bit rich compared with the company's net assets, but not extreme compared with its earnings and cash generation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-07-03) · fiscal Q1 2026 10-Q (period ended 2026-04-03) · fiscal Q3 2025 10-Q (period ended 2025-10-03) · fiscal Q2 2025 10-Q (period ended 2025-07-04) · FY2025 10-K (period ended 2026-01-02) · FY2024 10-K (period ended 2025-01-03) · FY2023 10-K (period ended 2023-12-29)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer